N/A
Completed N=193
Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Source: ClinicalTrials.gov NCT00902278 ↗
Enrolled (actual)
193
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcomePrimary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Summary
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY T Cell Responses Following Immunization |
1.5; 1.7; 1.9; 1.6; 2.4; 2.1 | — |
| SECONDARY Antibody Responses Following Immunization |
7.32; 7.02; 5.71; 5.26; 7.6; 7.2 | — |
Eligibility Criteria
Inclusion Criteria
- Adults (18-50 years of age)
- Willing to donate a blood sample multiple times
- Willing to sign informed consent and HIPAA
Exclusion Criteria
- Known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to chicken proteins
- Known hypersensitivity to neomycin, thimerosol (mercury derivative), neomycin, or polymyxin
- Previous life threatening reaction to influenza vaccine
- Individuals with altered immunocompetence state from medical condition ( HIV, cancer) or through immunosuppressive therapy(irradiation,corticosteroids, antimetabolites, alkylating agents, cytotoxic agents)
- Occurrence of neurological syndrome within six weeks of previous influenza immunization
- Active neurological disorder characterized by changing neurological disorder
- Pregnancy
- Acute febrile illness
- History of anemia or bleeding disorders
Data sourced from ClinicalTrials.gov (NCT00902278). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.